Patents Assigned to Nippon Chemiphar Co., Ltd.
  • Patent number: 12233071
    Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: February 25, 2025
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Toshiyasu Imai, Junzo Kamei
  • Patent number: 12202830
    Abstract: Provided is, for example, a method for producing a morphinan derivative represented by General Formula (II), including the step of: allowing metal sodium and ethylenediamine to act on a morphinan derivative represented by General Formula (I) in presence of an auxiliary solvent. wherein R1 represents a hydrogen atom, or a C1-10 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkenyl group, a C6-10 aryl group, or a heteroaryl group optionally having a substituent, R2 represents an amino protecting group, R3 represents a methoxy group, R4 and R5 represent a hydrogen atom or a hydroxy group, R6 and R7 represent a hydrogen atom or an electron-donating group, wherein R6 and R7 are not simultaneously a hydrogen atom, and X represents O or CH2.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: January 21, 2025
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Daisuke Saito, Kohei Hayashida
  • Publication number: 20240426818
    Abstract: Provided is a biochemical reaction substrate which can achieve higher test sensitivity and shorter testing time in an allergy test, which can also reduce a required amount of blood or the like needed as a specimen and decrease the number of test steps, thereby facilitating performance of the test, and which is to be used in an allergy test in which infection risk of the test staff is reduced.
    Type: Application
    Filed: August 6, 2024
    Publication date: December 26, 2024
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Kenji UEMURA, Norio Tanimoto, Mai Egami, Takahiro Mataki, Yumi Konishi, Motoe Shimizu, Shigenori Takahashi, Koji Sakaguchi
  • Publication number: 20240417379
    Abstract: A diazepine derivative represented by formula (I), where R1 and R2 represent hydrogen, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3, R4, R5, R6, and R7 each represents hydrogen, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen or sulfur, A represents benzene ring and the like, B represents NHC(?O) and the like, D and E each represents an atomic bond, G represents benzene which may be substituted, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 19, 2024
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi USHIODA, Kunio KOBAYASHI, Daisuke SAITO, Shogo SAKUMA, Toshiyasu IMAI, Kazuhide INOUE
  • Publication number: 20240374583
    Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.
    Type: Application
    Filed: July 17, 2024
    Publication date: November 14, 2024
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 12116351
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: October 15, 2024
    Assignee: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 12109209
    Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: October 8, 2024
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
  • Patent number: 12090158
    Abstract: The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: September 17, 2024
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventor: Toshiyasu Imai
  • Patent number: 12085560
    Abstract: Provided is a biochemical reaction substrate which can achieve higher test sensitivity and shorter testing time in an allergy test, which can also reduce a required amount of blood or the like needed as a specimen and decrease the number of test steps, thereby facilitating performance of the test, and which is to be used in an allergy test in which infection risk of the test staff is reduced.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: September 10, 2024
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Kenji Uemura, Norio Tanimoto, Mai Egami, Takahiro Mataki, Yumi Konishi, Motoe Shimizu, Shigenori Takahashi, Koji Sakaguchi
  • Publication number: 20240245636
    Abstract: Provided is a composition for increasing muscle mass in a mammal, the composition including citric acid, a salt of citric acid, a hydrate thereof, or a mixture thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 25, 2024
    Applicants: TOHOKU UNIVERSITY, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Michiaki ABE, Tetsuya AKAISHI, Kota ISHIZAWA, Toshiki NAKAI, Kazuhiko KAWAGUCHI, Satomi YAMASAKI, Koichiro NISHIOKA, Tetsuya SAKURAI
  • Publication number: 20240156796
    Abstract: The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression, the composition containing a selective ?-opioid receptor agonist as an active component, wherein the selective ?-opioid receptor agonist preferably also has a ?-opioid receptor antagonist action and a ?-opioid receptor antagonist action.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 16, 2024
    Applicants: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akiyoshi SAITOH, Daisuke YAMADA, Eriko NAKATA
  • Publication number: 20240091362
    Abstract: There is provided a method for producing a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof and having a moisture content of 4.0% by mass or less, the method including irradiating a composition containing a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof with microwaves.
    Type: Application
    Filed: March 28, 2022
    Publication date: March 21, 2024
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hideto TAKEDA, Nozomu SHIMAZAKI
  • Patent number: 11918589
    Abstract: A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof or a hydrate or solvate thereof as an active ingredient.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 5, 2024
    Assignees: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Toshiyasu Imai, Toru Kawasaki, Toru Ogawa, Kazuhide Inoue
  • Publication number: 20230312570
    Abstract: Provided is a method which is for preparing a morphinan derivative having a diaryl ether skeleton represented by general formula (III) (In the formula, R1 represents a hydrogen atom, etc., R2, R3, and R4 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc., R5 represent a hydrogen atom, a hydroxy group, etc., R14 and R15 are the same or different and each represent a hydrogen atom, or an arbitrary substituent, etc.), and in which a phenyl group is introduced into the 4-position phenol of a morphinan derivative through the Ullmann reaction of a system using a monovalent copper compound or a novel catalytic system simultaneously using a monovalent copper compound and zero-valent metallic copper.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 5, 2023
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventor: Masaaki HIROSE
  • Publication number: 20230248738
    Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
    Type: Application
    Filed: April 17, 2023
    Publication date: August 10, 2023
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Toshiyasu IMAI, Junzo KAMEI
  • Patent number: 11666582
    Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 6, 2023
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Toshiyasu Imai, Junzo Kamei
  • Publication number: 20230159530
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: January 9, 2023
    Publication date: May 25, 2023
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Publication number: 20230141198
    Abstract: The present invention provides a compound having a selective opioid ? receptor agonist effect. The present invention provides a pyrazolomorphinan derivative represented by general formula (1) (in the formula, (II) R1 represents a hydrogen atom, an alkyl group, a cycloalkylmethyl group, or the like, R2 represents a hydrogen atom or a hydroxy protecting group, R3 represents a hydroxy group, an alkyl group, a partially unsaturated heterocyclic group, an aryl group, a heteroaryl group, or the like; and R4 represents a hydrogen atom, an alkyl group, an aralkyl group, a cycloalkyl group, a cycloalkyl alkyl group, a saturated heterocyclic group, an aryl group, a heteroaryl group, or the like). The pyrazolomorphinan derivative can be used as an active ingredient in an analgesic, an antidepressant, an anxiolytic, or the like.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 11, 2023
    Applicants: THE KITASATO INSTITUTE, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hideaki FUJII, Shigeto HIRAYAMA, Yoshikazu WATANABE
  • Patent number: 11643411
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: May 9, 2023
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
  • Publication number: 20230132191
    Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.
    Type: Application
    Filed: December 15, 2022
    Publication date: April 27, 2023
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA